Assessing Epidemiological Data Points The findings from this study echo that of another by Trivella and colleagues, also published in Hepatology Communications. This 2023 study is a literature review ...

Patients with neuromyelitis optica spectrum disorder (NMOSD) should be closely followed on the lookout for other inflammatory and immunological conditions, according to a study recently published in ...

A new phase 2 clinical trial to test the safety, efficacy, and tolerability of TAK-411 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) is now open. The open-label, ...

The use of some patient-reported, disease-specific quality of life (QoL) scales in hereditary angioedema (HAE) are moderately recommended, according to a study published in Health and Quality of Life ...

Yiannis Papazoglou is one of only 40 people in the world with a mutation of the IRF2BPL gene. Foundation Aims to Help Patients With Rare Diseases—Even Before They’re Recognized The Undiagnosed ...

Transcutaneous bilirubin (TcB) and serum bilirubin (SB) concentrations may differ across patients of various ethnicities, according to a study published in Children. Bilirubin levels are almost always ...

Prophylactic treatment with cyclophosphamide against graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis (MF) is “extremely effective, ...

Although primary intraosseous Rosai-Dorfman disease (RDD) may be characterized by fibrosis and an increase in Ig4+ plasma concentration, it does not meet the diagnostic criteria for immunoglobulin ...

A CRISPR/Cas9-modified Janus kinase 2 (JAK2) V617F model may be useful to develop new therapies against myeloproliferative neoplasms (MPNs), showed a new study published in the International Journal ...

Adult patients with Fabry disease have a lower lean mass compared to healthy people, according to a new study published in the Journal of Rare Diseases. The accumulation of lyso-Gb3 is also correlated ...

Gastrointestinal (GI) symptoms are the second most frequent clinical manifestation of systemic mastocytosis (SM), after itching. They affect 15% to 85% of patients and have a significant impact on ...

Individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) undergoing treatment with fludarabine, cyclophosphamide, and rituximab (FCR) are at increased risk for other ...